Mutual Funds & ETFs
Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
MarketMinute.com Stock News
September 24, 2012 at 11:53 AM EDT
Peregrine Discovers Trial Discrepancies
Peregrine Pharmaceuticals Inc. (
) discovered major discrepancies in a Phase II trial of its lung cancer treatment bavituximab conducted by a third party sending the stock price plummeting $4.15 to $1.24.
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Bots go here